-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Eosinophilic gastrointestinal disorder (EGID) is a collective term for a group of diseases, including eosinophilic esophagitis (EoE), eosinophilic gastritis (EG), and Eosinophilic gastroenteritis (eosinophilic gastroenteritis, EGE), eosinophilic enteritis and eosinophilic colitis (eosinophilic colitis, EC)
.
In patients with eosinophilic gastritis and eosinophilic gastroenteritis, excess eosinophils can cause a variety of potentially debilitating gastrointestinal symptoms, including abdominal pain, vomiting, and diarrhea
FDA
Since EG/EGE is relatively rare, there are not many data on its prevalence
.
According to previous survey data, the prevalence of EGE in the United States is estimated to be 22/100,000
Recently, AstraZeneca IL-5 inhibitors Fasenra (Tony Canary natalizumab) has received US Food and Drug Administration fast-track designation Bureau, for the treatment of eosinophilic gastritis (EG), with or without Eosinophilic gastroenteritis (EGE)
.
The biological therapy has also received orphan drug designation from the FDA for the treatment of EG and EGE
manage
AZ is launching a phase III clinical trial called HUDSON to evaluate the efficacy and safety of Fasenra in patients with EG and/or EGE
.
.
AZ is launching a phase III clinical trial called HUDSON to evaluate the efficacy and safety of Fasenra in patients with EG and/or EGE
Blood vessel
Original source:
Original source:https:// href="https://" target="_blank" rel="noopener">https:// https:// Leave a message here